OmniAb (OABI) Non-Current Deferred Tax Liability (2021 - 2026)
OmniAb's (OABI) quarterly Non-Current Deferred Tax Liability came in at $1.2 million in Q1 2026, down 44.43% year-on-year from $2.2 million in Q1 2025, and up 56.31% on a QoQ basis from $785000.0 in Q4 2025.
OmniAb (OABI) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at $1.2 million in Q1 2026.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 44.43% year-over-year to $1.2 million in Q1 2026; TTM through Mar 2026 was $1.2 million, a 44.43% decrease from a year earlier, with the FY2025 full-year figure at $785000.0, down 66.08% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $1.2 million, up from $785000.0 in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for OABI reached as high as $38.1 million in Q4 2023 and fell as low as $785000.0 in Q4 2025.
- Historically, Non-Current Deferred Tax Liability has averaged $10.0 million across 5 years, with a median of $5.5 million in 2024.
- Across the five-year window, Non-Current Deferred Tax Liability jumped 78.6% in 2023 and plunged 93.93% in 2024, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $21.3 million in 2022, then soared by 78.6% to $38.1 million in 2023, then plunged by 93.93% to $2.3 million in 2024, then slumped by 66.08% to $785000.0 in 2025, then surged by 56.31% to $1.2 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $1.2 million in Q1 2026, $785000.0 in Q4 2025, and $1.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | OmniAb | 261.62 Mn | 212.55 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.23 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 785,000.00 |
| Dec 31, 2025 | 785,000.00 |
| Sep 30, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Mar 31, 2024 | 8.74 Mn |
| Mar 31, 2024 | 8.74 Mn |
| Dec 31, 2023 | 38.11 Mn |
| Dec 31, 2023 | 38.11 Mn |